Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Abstract Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy‐resistant melanomas. Unfortunately, our data show that this combination elicits a heterogeneous response in a panel of melanoma cell line...

Full description

Bibliographic Details
Main Authors: Alireza Azimi, Stefano Caramuta, Brinton Seashore‐Ludlow, Johan Boström, Jonathan L Robinson, Fredrik Edfors, Rainer Tuominen, Kristel Kemper, Oscar Krijgsman, Daniel S Peeper, Jens Nielsen, Johan Hansson, Suzanne Egyhazi Brage, Mikael Altun, Mathias Uhlen, Gianluca Maddalo
Format: Article
Language:English
Published: Springer Nature 2018-03-01
Series:Molecular Systems Biology
Subjects:
CDK2
Hsp90 and BRAF inhibitors
melanoma
MITF
proteomics
Online Access:https://doi.org/10.15252/msb.20177858

Internet

https://doi.org/10.15252/msb.20177858

Similar Items